Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 2/20 | 0.52 |
| ▸ | MITF | O75030 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | HBB | P68871 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | NOS1 | P29475 | 8/20 | 0.50 |
| ▸ | PNP | P00491 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pterine SCHEMBL64320 | 0.98 | AKR1B1 (0.54) | AKR1B1THRBMITFTP53ALOX15 | |
| Pterine SCHEMBL29364680 | 0.98 | AKR1B1 (0.54) | AKR1B1THRBMITFTP53ALOX15 | |
| Pterine SCHEMBL28042087 | 0.96 | AKR1B1 (0.53) | AKR1B1THRBMITFTP53ALOX15 | |
| Pterine SCHEMBL30474634 | 0.96 | AKR1B1 (0.53) | AKR1B1THRBMITFTP53ALOX15 | |
| Pterine SCHEMBL27566961 | 0.96 | AKR1B1 (0.53) | AKR1B1THRBMITFTP53ALOX15 | |
| Pterine SCHEMBL31296557 | 0.96 | AKR1B1 (0.53) | AKR1B1THRBMITFTP53ALOX15 | |
| Pterine SCHEMBL31190985 | 0.96 | AKR1B1 (0.53) | AKR1B1THRBMITFTP53ALOX15 | |
| Pterine SCHEMBL5703596 | 0.96 | AKR1B1 (0.53) | AKR1B1THRBMITFTP53ALOX15 | |
| Pterine SCHEMBL452642 | 0.96 | AKR1B1 (0.53) | AKR1B1THRBMITFTP53ALOX15 | |
| Pterine SCHEMBL27339749 | 0.96 | AKR1B1 (0.53) | AKR1B1THRBMITFTP53ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160015711-A1 | CALCIUM PTERIN-6-CARBOXYLATE (CaPTERIN-6-COOH) AS A NOVEL IMMUNO-THERAPEUTIC | SANRX PHARMACEUTICALS, INC. | 2016-01-21 | — | — | US | claimed |
| US-20120251495-A1 | PTERIN BASED THERAPIES FOR INFLAMMATORY CONDITIONS | SANRX PHARMACEUTICALS, INC. | 2012-10-04 | — | — | US | claimed |
| CN-101977607-A | Pterin based therapies for inflammatory conditions | SANRX PHARMACEUTICALS INC | 2011-02-16 | — | — | CN | claimed |
| EP-2276489-A2 | PTERIN BASED THERAPIES FOR INFLAMMATORY CONDITIONS | Sanrx Pharmaceuticals, Inc. (US) | 2011-01-26 | — | — | EP | claimed |
| WO-2009092050-A2 | PTERIN BASED THERAPIES FOR INFLAMMATORY CONDITIONS | SANRX PHARMACEUTICALS, INC. (US) | 2009-07-23 | — | — | WO | claimed |
| US-20170143720-A1 | CALCIUM FOLATE (CAFOLATE) AND THERAPEUTIC METHODS BASED THEREON | SANRX PHARMACEUTICALS INC (US) | 2017-05-25 | — | — | US | disclosed |
| US-20160015711-A1 | CALCIUM PTERIN-6-CARBOXYLATE (CaPTERIN-6-COOH) AS A NOVEL IMMUNO-THERAPEUTIC | SANRX PHARMACEUTICALS, INC. | 2016-01-21 | — | — | US | disclosed |
| US-20150010509-A1 | CALCIUM FOLATE (CAFOLATE) AND THERAPEUTIC METHODS BASED THEREON | SANRX PHARMACEUTICALS, INC. (US) | 2015-01-08 | — | — | US | disclosed |
| WO-2013116238-A1 | CALCIUM FOLATE (CAFOLATE) AND THERAPEUTIC METHODS BASED THEREON | SANRX PHARMACEUTICALS, INC. (US) | 2013-08-08 | — | — | WO | disclosed |
| US-20120251495-A1 | PTERIN BASED THERAPIES FOR INFLAMMATORY CONDITIONS | SANRX PHARMACEUTICALS, INC. | 2012-10-04 | — | — | US | disclosed |
| US-20120251495-A1 | PTERIN BASED THERAPIES FOR INFLAMMATORY CONDITIONS | SANRX PHARMACEUTICALS, INC. | 2012-10-04 | — | — | US | disclosed |
| EP-2094715-B1 | DIPTERINYL CALCIUM PENTAHYDRATE (DCP) AND THERAPEUTIC METHODS BASED THEREON | SANRX PHARMACEUTICALS INC (US) | 2012-08-29 | — | — | EP | disclosed |
| US-20100105692-A1 | Dipterinyl Calcium Pentahydrate (DCP) and Therapeutic Methods Based Thereon | MOHENO PHILLIP | 2010-04-29 | — | — | US | disclosed |
| CN-101663308-A | Dipterinyl calcium pentahydrate (dcp) and therapeutic methods based thereon | SANRX PHARMACEUTICALS INC | 2010-03-03 | — | — | CN | disclosed |
| US-7662820-B2 | Dipterinyl calcium pentahydrate (DCP) and therapeutic methods based thereon | SANRX PHARMACEUTICALS, INC. (US) | 2010-02-16 | — | — | US | disclosed |
| EP-2094715-A2 | DIPTERINYL CALCIUM PENTAHYDRATE (DCP) AND THERAPEUTIC METHODS BASED THEREON | Sanrx Pharmaceuticals, Inc. (US) | 2009-09-02 | — | — | EP | disclosed |
| WO-2009092050-A2 | PTERIN BASED THERAPIES FOR INFLAMMATORY CONDITIONS | SANRX PHARMACEUTICALS, INC. (US) | 2009-07-23 | — | — | WO | disclosed |
| WO-2009092050-A2 | PTERIN BASED THERAPIES FOR INFLAMMATORY CONDITIONS | SANRX PHARMACEUTICALS, INC. (US) | 2009-07-23 | — | — | WO | disclosed |
| US-20080166355-A1 | Dipterinyl calcium pentahydrate (DCP) and therapeutic methods based thereon | SANRX PHARMACEUTICALS, INC. (US) | 2008-07-10 | — | — | US | disclosed |
| WO-2008054793-A2 | DIPTERINYL CALCIUM PENTAHYDRATE (DCP) AND THERAPEUTIC METHODS BASED THEREON | SANRX PHARMACEUTICALS, INC. (US) | 2008-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170143720-A1 | CALCIUM FOLATE (CAFOLATE) AND THERAPEUTIC METHODS BASED THEREON | FOLR1, FOLR2, IL6 | AKR1B1 431/4885THRB 942/4885MITF 4797/4885 |
| US-20100105692-A1 | Dipterinyl Calcium Pentahydrate (DCP) and Therapeutic Methods Based Thereon | CACYBP, ORAI1, CALCR | AKR1B1 3105/4885THRB 1944/4885MITF 2334/4885 |
| US-20080166355-A1 | Dipterinyl calcium pentahydrate (DCP) and therapeutic methods based thereon | CACYBP, ORAI1, CALCR | AKR1B1 3105/4885THRB 1944/4885MITF 2334/4885 |
| US-20120251495-A1 | PTERIN BASED THERAPIES FOR INFLAMMATORY CONDITIONS | VDR, S100P, TLR6 | AKR1B1 962/4885THRB 2302/4885MITF 4295/4885 |
| US-20150010509-A1 | CALCIUM FOLATE (CAFOLATE) AND THERAPEUTIC METHODS BASED THEREON | FOLR1, FOLR2, IL6 | AKR1B1 431/4885THRB 942/4885MITF 4797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.